insights_auto
Why is DMN up 2,67%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
0,073 €
arrow_upward
+2,67%(+0,0019) 1D
5 նոյ, 16:36:09 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
148,01 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
148,01 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
Yahoo Finance
·
17 րոպե առաջ
This Year’s Worst S&P 500 Stock Just Got a Huge Reprieve
GV Wire
·
4 րոպե առաջ
Nasdaq Set to Confirm Correction as AI Spending Worries Mount
MarketWatch
·
22 րոպե առաջ
Bloom Energy’s stock is one of the S&P 500’s biggest losers amid fears of data-center delays
ABC News - Breaking News, Latest News and Videos
·
36 րոպե առաջ
Dow plunges 1,200 points, Nasdaq into correction territory after midterm results stock rally
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB